Jörg Seraphin

Second-Line Oxaliplatin, Folinic Acid, and Fluorouracil Versus Folinic Acid and Fluorouracil Alone for Gemcitabine-Refractory Pancreatic Cancer: Outcomes From the CONKO-003 Trial

Helmut Oettle, Hanno Riess, Jens Stieler et al. · Journal of Clinical Oncology · 2014 · 484 citations

Medicine, Oncology, Pharmacology +13

Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: A phase III-study from the German CONKO-study group

Uwe Pelzer, Ingo Schwaner, Jens Stieler et al. · European Journal of Cancer · 2011 · 380 citations

Medicine, Oncology, Chemotherapy +10

Phase <scp>III</scp> randomized, double‐blind study of paclitaxel with and without everolimus in patients with advanced gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum‐containing regimen (<scp>RADPAC</scp>)

Sylvie Lorenzen, Jorge Riera Knorrenschild, Claudia Pauligk et al. · International Journal of Cancer · 2020 · 30 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Molecular cytogenetic monitoring from CD34+ peripheral blood cells in myelodysplastic syndromes: First results from a prospective multicenter German diagnostic study

Friederike Braulke, Klaus Jung, Julie Schanz et al. · Leukemia Research · 2013 · 26 citations

Medicine, Genetics, Hematology +15

A randomized, double-blind, multicenter phase III study evaluating paclitaxel with and without RAD001 in patients with gastric cancer who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC).

Salah‐Eddin Al‐Batran, Jorge Riera‐Knorrenschild, Claudia Pauligk et al. · Journal of Clinical Oncology · 2017 · 22 citations

Medicine, Oncology, Pharmacology +12